Navigation Links
Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184
Date:2/3/2012

CAMBRIDGE, Mass., Feb. 3, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the partial clinical hold on IDX184 has been removed and that the Company's 12-week phase IIb study evaluating IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV) may continue. IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection is a pan-genotypic oral nucleotide polymerase inhibitor, and has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies. Recently announced interim phase IIb data demonstrated favorable antiviral activity and no serious adverse events.

"After review of the interim safety and antiviral activity results from the IDX184 phase IIb clinical trial, the FDA removed the partial clinical hold and has allowed us to continue enrollment of this study," Ron Renaud, President and Chief Executive Officer of Idenix, commented. "Importantly, this allows us to expand the phase IIb program and evaluate IDX184 in interferon-free combination regimens with other direct-acting antivirals. We are working toward beginning all-oral combination trials as quickly as possible."

About IDX184 Phase IIb Study

In July 2011, Idenix initiated enrollment of treatment-naive genotype 1 HCV-infected patients into a randomized, double-blind, parallel group phase IIb clinical trial of IDX184. The study features two treatment arms, either 50 mg or 100 mg of IDX184 administered once-daily for 12 weeks, each arm in combination with PegIFN/RBV. Study objectives include safety and tolerability, and antiviral activity endpoi
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... health, has appointed Holly B. Bauzon as ... Ms. Bauzon has a proven track record in both ... services companies. She has more than 20 years of ... held the position of Director, Lab Services Sales and ...
(Date:8/21/2014)... Aug. 21, 2014  eRelevance Corporation ( www.erelevancecorp.com ... today that it has completed integration with Nextech, ... Plastic Surgery and Dermatology practices. "Integration ... to healthcare practices using Nextech," stated Bob ... "Using information from the EMR we are able ...
(Date:8/21/2014)... YORK , Aug. 21, 2014  Publicis Groupe ... Shannon Hartley , Managing Partner and Healthcare Industry Group ... PharmaVoice 100, which recognizes the most inspiring people in ... are leaders in research and development, marketing, technology, creativity, ... agency in 2006 as a partner in its leading ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Shannon Hartley Shines in PharmaVOICE 100 2
(Date:8/22/2014)... August 22, 2014 Dealing with a drug ... when the addict is a child. Adolescent substance abuse has ... a long time. But a new helpline is now providing ... professional youth rehab for something like a teen drug ... designed to help make a positive impact in the community. ...
(Date:8/22/2014)... August 22, 2014 According to ... System and Adaptive Cruise Control (ACC) System Market ... Forecasts 2014 - 2019", published by MarketsandMarkets, classifies ... Market in terms of volume and value. The ... years as well as covers review of the ...
(Date:8/21/2014)... August 22, 2014 The natural loss of ... lines, wrinkles and sagging of skin. Using products to ... age 40, the body has lost about 15% of it ... 45%," says Kathy Heshelow, founder of Sublime Beauty®. "Collagen ... it - well, we know what happens." , Collagen in ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Local agencies ... have larger discounts for specific protection plans, according to ... helping consumers to quote life insurance from local agencies ... The local agents that appear inside of the national ... fast method of price reviews this year. Adults who ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 AVEC ... to announce the addition of Kerry Gillespie as ... of healthcare management experience, Gillespie brings an extremely ... multiple executive management positions with prominent industry leading ... served as President of Triad Isotopes, Inc. a ...
Breaking Medicine News(10 mins):Health News:Cincinnati’s New Troubled Teen Helpline is Making a Difference in the Community 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 3Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 4Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 2Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Kerry Gillespie Appointed as Chief Executive Officer of AVEC Health Solutions 2
... campuses of the University of California has found that flash-heating ... virus. ,The researchers hope that this technique - ... pan of water over a flame or single burner - ... nations will soon be able to more safely feed their ...
... rigorous U.S. trial comparing two traditional operations for stress ... urologists and urogynecologists supported by the National Institutes of ... more women achieve dryness than the Burch technique. ... a meticulous, relatively long-term comparison of these common surgeries ...
... given people another reason to quit smoking, by finding that ... depression in comparison to those who never smoke. ,The ... an elevated risk of depressive symptoms in short run, this ... long run. ,In other words, both completely ...
... Well, it doesnt have to be that way ... say that they have successfully managed to reduce ... containing vitamin A. ,Not only did the ... 23 people revealed it boosted levels of important skin ...
... a condition that most people prefer not to talk about, ... this embarrassing problem. It's called overactive bladder (OAB) and ... sometimes causing urine leakage. ,Now, to reduce the ... using nerve stimulation in the ankle to better help control ...
... chronic gum disease periodontitis, may have an increased risk of ... ,Periodontitis is an oral infection thought to be caused by ... well. ,The study was conducted by a team ... of New York at Buffalo and the Roswell Park Cancer ...
Cached Medicine News:Health News:Flash-heating Inactivates HIV in Breast Milk: Study 2Health News:Flash-heating Inactivates HIV in Breast Milk: Study 3Health News:Sling Surgery Better Than Burch for Treating Stress Incontinence in Women 2Health News:Sling Surgery Better Than Burch for Treating Stress Incontinence in Women 3Health News:Regular Smokers are at the Risk of Developing Depression 2Health News:Wrinkles can Be Really Ironed Out, Thanks to Vitamin A 2Health News:Stimulating the Ankle Can Help Patients With Overactive Bladder 2Health News:Men With Chronic Gum Disease at Higher Risk of Tongue Cancer 2
... take the words "mobile operating table" literally! The ... important functions of a general purpose operating table ... For table operations, a cable connected hand control, ... available. Plus, there is a control panel at ...
... carbon fiber c-arm table allows 50 ... brachytherapy, gynecology, gastroenterology, cardiovascular, orthopedic, ENT, ... design allows easy access for all ... 16-inch elevating travel, 16-inch longitudinal travel, ...
... for procedures where stability, access, and ... A cantilevered low attenuation carbon fiber ... The radiolucent area is free of ... and unobstructed C-Arm positioning. Functional design ...
... Lyphochek Elevated Immunosuppressant Control is a bilevel ... blood. This unique product is ideal for ... high Cyclosporine levels, such as C2 monitoring, ... at two hours post-dose., ,Lyphochek Elevated Immunosuppressant ...
Medicine Products: